Dani Bancroft, Author at Labiotech.eu

About

Former Editor, now flitting back and forth as a freelancer. Originally from London and studied Zoology at the University of Reading, UK. Previous work includes having written for The Spark University Newspaper and the Wellcome Trust.

Articles by Dani Bancroft

News and Trends 30 Nov 2015

Heptares’ G-Protein StaR Platform has now Hooked Pfizer in a Billion Euro Deal

Heptares Therapeutics from the UK has landed Pfizer in a huge potential $1.9Bn deal for their G-protein receptor platform. Heptares Therapeutics was founded by Fiona Marshall (one of our Top 10 UK Women in Biotech), who now serves as a CSO to Japanese Big boss Sosei, which wholly acquired Heptares earlier this year in a […]

November 30, 2015 - 2 minutesmins - By Dani Bancroft

regeneron sanofi praulant odyssey alirocumab cardiac statins

News and Trends 27 Nov 2015

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Sanofi & Regeneron have completed enrollment in the global Phase III for Praulent (alirocumab), which is evaluating its potential cardiovascular benefits for patients with acute coronary syndrome (ACS). The ‘Odyssey Outcomes’ Study has enrolled around 18,000 patients for its trial (phwoar), and if it shows positive results could be a huge success for Sanofi and […]

November 27, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 27 Nov 2015

Could this new TCR Lung Cancer Trial Save Adaptimmune from a Volatile Stock Situation?

Adaptimmune has initiated a phase I/II safety and tolerability study of its affinity enhanced T-cell therapy targeting the NY-ESO-1 cancer antigen in patients with non-small cell lung cancer (NSCLC). Adaptimmune is developing the affinity enhanced T-cell therapy targeting the NY-ESO-1 antigen under a collaboration agreement with GlaxoSmithKline (GSK). Located in Oxford (UK) this clinical stage […]

November 27, 2015 - 3 minutesmins - By Dani Bancroft

twb greentech yeast enobraq carbon hydrocarbon

News and Trends 26 Nov 2015

A €1.3M Start-Up is Engineering Baker’s Yeast to Make Green House Gases Useful

Culturing yeast cells to absorb CO2 could be the Green way forward for this new French Start-up. As a spin off Toulouse White Biotechnologies (TWB) project, the seed investor in its €1.3M Green Seed Fund is the lead French VC Sofinnova. TWB, a pre-industrial demonstrator in the field of industrial biotechnology managed by INRA (the […]

November 26, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Ablynx – the Belgian Nanobody biotech (which uses monoclonal antibodies of Alpacas) has entered a new and exclusive partnership with the Danish Novo Nordisk on a mysterious disease… Ablynx are famously well connected in the biotech industry, with many huge pharmas licensing out their Alpaca-nanobody tech. Partnerships include AbbVie (Immunology), Boehringer Ingelheim, Genzyme (Multiple Sclerosis/CNS), […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

The UK-Israeli €378M Small-Molecule Offensive Against Migraines

The Israeli TEVA and UK Heptares Therapeutics (now owned by Japanese Sosei) have partnered up on novel drug therapies targeting Migraines. The pain and disruption migraines can cause pain that lasts from 4 to 72 hours, and around 10 million worldwide suffer such episodes on a regular basis. Signs and symptoms of a migraine include photosensitivity […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

biosimilar war neulasta herceptin avastin rituxan1

News and Trends 25 Nov 2015

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Novartis is hitting back in the Biosimilar battleground: now Neulasta, the white blood cell booster for Cancer, is the latest of Amgen’s victims… Neulasta (pegfilgrastim) has been submitted through Novartis’ subsidiary, Sandoz. As a recombinant human granulocyte colony-stimulating factor (G-CSF), pegfilgrastim looks to stimulate the immune system and boost the white cell count. Neulasta is […]

November 25, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 24 Nov 2015

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

The World Leader in the Immuno-Oncology field has teamed up with a major German Investor to better identify breakthrough investment opportunities across the EU. Bristol-Myers Squibb (BMS) has partnered with Life Sciences Partners in Munich to highlight novel immuno-oncology technologies which could be the next blockbusters in the field. Together the two have conspired a […]

November 24, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 24 Nov 2015

2015 Review: What Exciting Developments Have Been Made in Neurodegenerative Disease?

Since both Alzheimer’s Disease and Parkinson’s combined affect up to 50 million people worldwide, it is no wonder this new wave of break-through milestones is getting the industry excited… The Central Nervous System (CNS) comprises many complex tissues and highly specialized cell types, mutation in which can cause an array of deadly and chronic diseases. […]

November 24, 2015 - 9 minutesmins - By Dani Bancroft

women in biotech movers shakers 2015 biobeats

News and Trends 20 Nov 2015

Get to Know the Top 50 Women in the UK’s Biotech Scene

The Movers & Shakers Report 2015 lists 50 of the Top female Bio-Entrepreneurs… here’s a select few I found particularly impressive in the Biotech Industry! Written by Miranda Weston-Smith, the BioBeat15 report is sponsored by Horton Ruston Poole, Johnson & Johnson Innovation, MedImmune and Pfizer to celebrate what women working in bio-business have brought to […]

November 20, 2015 - 5 minutesmins - By Dani Bancroft

frits ahlefeldt cellectis servier pfizer ucart leukemia1

News and Trends 19 Nov 2015

Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas at Once?

French Servier and Pfizer have already had independent partnerships with Cellectis on various R&D areas. But now the two have signed a joint partnership on Cellectis’s leading product UCART19 for blood cancer. This unusual move only further feeds the rumours of Pfizer’s potential future acquisition of Cellectis. As we’ve discussed before, Cellectis has moved most […]

November 19, 2015 - 3 minutesmins - By Dani Bancroft

catapult cell therapy manufacturing facility uk

News and Trends 18 Nov 2015

The UK Catapults Cell Therapy Manufacture into Europe with a €78.5M New Facility

The UK Government’s Innovate has invested over €78.5M into a new Cell-therapy manufacturing facility for the major UK biotech Catapult Cell Therapy to be located in the growing Biotech cluster in Stevenage. Catapult is a big deal in the UK Biotech scene (apparently) and their division in Cell therapeutics founded in 2012 already has a […]

November 18, 2015 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Dani Bancroft

About

Articles by Dani Bancroft

Heptares’ G-Protein StaR Platform has now Hooked Pfizer in a Billion Euro Deal

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Could this new TCR Lung Cancer Trial Save Adaptimmune from a Volatile Stock Situation?

A €1.3M Start-Up is Engineering Baker’s Yeast to Make Green House Gases Useful

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

The UK-Israeli €378M Small-Molecule Offensive Against Migraines

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

2015 Review: What Exciting Developments Have Been Made in Neurodegenerative Disease?

Get to Know the Top 50 Women in the UK’s Biotech Scene

Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas at Once?

The UK Catapults Cell Therapy Manufacture into Europe with a €78.5M New Facility

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Dani Bancroft

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!